Manasanch, Elisabet E.
Orlowski, Robert Z.
Article History
First Online: 24 January 2017
Competing interests
: R.Z.O. has served on advisory boards for Amgen, which developed and markets carfilzomib, and for Takeda Pharmaceuticals, which developed and markets bortezomib and ixazomib, and has received research support from these companies for clinical and laboratory projects. E.E.M. declares no competing interests.
Free to read: This content has been made available to all.